» Articles » PMID: 37364789

EASL Clinical Practice Guidelines on Acute-on-chronic Liver Failure

Overview
Journal J Hepatol
Publisher Elsevier
Specialty Gastroenterology
Date 2023 Jun 26
PMID 37364789
Affiliations
Soon will be listed here.
Abstract

Acute-on-chronic liver failure (ACLF), which was described relatively recently (2013), is a severe form of acutely decompensated cirrhosis characterised by the existence of organ system failure(s) and a high risk of short-term mortality. ACLF is caused by an excessive systemic inflammatory response triggered by precipitants that are clinically apparent (e.g., proven microbial infection with sepsis, severe alcohol-related hepatitis) or not. Since the description of ACLF, some important studies have suggested that patients with ACLF may benefit from liver transplantation and because of this, should be urgently stabilised for transplantation by receiving appropriate treatment of identified precipitants, and full general management, including support of organ systems in the intensive care unit (ICU). The objective of the present Clinical Practice Guidelines is to provide recommendations to help clinicians recognise ACLF, make triage decisions (ICU vs. no ICU), identify and manage acute precipitants, identify organ systems that require support or replacement, define potential criteria for futility of intensive care, and identify potential indications for liver transplantation. Based on an in-depth review of the relevant literature, we provide recommendations to navigate clinical dilemmas followed by supporting text. The recommendations are graded according to the Oxford Centre for Evidence-Based Medicine system and categorised as 'weak' or 'strong'. We aim to provide the best available evidence to aid the clinical decision-making process in the management of patients with ACLF.

Citing Articles

Interprofessional Therapeutic Drug Monitoring of Piperacillin/Tazobactam Enhances Care for Patients with Acute-on-Chronic Liver Failure in the ICU: A Retrospective Observational Pilot Study.

Schmid S, Zimmermann K, Koch C, Mester P, Athanasoulas G, Buttenschoen J Antibiotics (Basel). 2025; 14(2).

PMID: 40001445 PMC: 11851559. DOI: 10.3390/antibiotics14020202.


Iodine-131 Combined With Plasma Exchange Treatment in Graves' Hyperthyroidism Patients With Severe Liver Injury Whose Average Model for End-Stage Liver Disease Scores >20.

Zhu X, Ding R, Wang B, Yang Y, Ta F, Wang Y Gastro Hep Adv. 2025; 4(4):100600.

PMID: 39996246 PMC: 11849068. DOI: 10.1016/j.gastha.2024.100600.


Analysis of the prognostic efficacy of syndecan-1 for patients with ACLF and its functional role in liver regeneration.

He Y, Zhang X, Yao Y, Li J, Fu S, Feng Y BMC Med. 2025; 23(1):104.

PMID: 39985044 PMC: 11846419. DOI: 10.1186/s12916-025-03931-4.


Acute-on-chronic liver failure (ACLF): the 'Kyoto Consensus'-steps from Asia.

Choudhury A, Kulkarni A, Arora V, Soin A, Dokmeci A, Chowdhury A Hepatol Int. 2025; 19(1):1-69.

PMID: 39961976 PMC: 11846769. DOI: 10.1007/s12072-024-10773-4.


Long-term efficacy and safety of tenofovir alafenamide, tenofovir disoproxil fumarate, and entecavir in treating hepatitis B virus-related acute-on-chronic liver failure: A 144-week data analysis.

Zhang Y, Xu W, Deng Z, Wang L, Zheng X, Zhu X Liver Res. 2025; 8(4):295-303.

PMID: 39958923 PMC: 11771274. DOI: 10.1016/j.livres.2024.10.001.